Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The cellular basis of protease-activated receptor 2–evoked mechanical and affective pain
Shayne N. Hassler, Moeno Kume, Juliet M. Mwirigi, Ayesha Ahmad, Stephanie Shiers, Andi Wangzhou, Pradipta R. Ray, Serge N. Belugin, Dhananjay K. Naik, Michael D. Burton, Josef Vagner, Scott Boitano, Armen N. Akopian, Gregory Dussor, Theodore J. Price
Shayne N. Hassler, Moeno Kume, Juliet M. Mwirigi, Ayesha Ahmad, Stephanie Shiers, Andi Wangzhou, Pradipta R. Ray, Serge N. Belugin, Dhananjay K. Naik, Michael D. Burton, Josef Vagner, Scott Boitano, Armen N. Akopian, Gregory Dussor, Theodore J. Price
View: Text | PDF
Research Article Neuroscience

The cellular basis of protease-activated receptor 2–evoked mechanical and affective pain

  • Text
  • PDF
Abstract

Protease-activated receptor 2 (PAR2) has long been implicated in inflammatory and visceral pain, but the cellular basis of PAR2-evoked pain has not been delineated. Although PAR2-evoked pain has been attributed to sensory neuron expression, RNA-sequencing experiments show ambiguous F2rl1 mRNA detection. Moreover, many pharmacological tools for PAR2 are nonspecific, acting also on the Mas-related GPCR family (Mrg) that are highly enriched in sensory neurons. We sought to clarify the cellular basis of PAR2-evoked pain. We developed a PAR2–conditional knockout mouse and specifically deleted PAR2 in all sensory neurons using the PirtCre mouse line. Our behavioral findings show that PAR2 agonist–evoked mechanical hyperalgesia and facial grimacing, but not thermal hyperalgesia, are dependent on PAR2 expression in sensory neurons that project to the hind paw in male and female mice. F2rl1 mRNA is expressed in a discrete population (~4%) of mostly small-diameter sensory neurons that coexpress the Nppb and IL31ra genes. This cell population has been implicated in itch, but our work shows that PAR2 activation in these cells causes clear pain-related behaviors from the skin. Our findings show that a discrete population of DRG sensory neurons mediate PAR2-evoked pain.

Authors

Shayne N. Hassler, Moeno Kume, Juliet M. Mwirigi, Ayesha Ahmad, Stephanie Shiers, Andi Wangzhou, Pradipta R. Ray, Serge N. Belugin, Dhananjay K. Naik, Michael D. Burton, Josef Vagner, Scott Boitano, Armen N. Akopian, Gregory Dussor, Theodore J. Price

×

Figure 9

Activation of PAR2+ sensory neurons via low-dose intradermal administration of 2AT induces pain but not itch bouts.

Options: View larger image (or click on image) Download as PowerPoint
Activation of PAR2+ sensory neurons via low-dose intradermal administrat...
The subset of sensory neurons that express F2rl1 mRNA also express several markers, such as the IL-31R, implicated in itch. We investigated the role of PAR2 activation in this subset of sensory neurons via the cheek scratch versus wipe assay. This assay differentiates itch and pain behaviors in mice through hind limb scratching and forelimb wiping, respectively. After habituation, baseline behavior was video-taped for 15 minutes before injection. Intradermal injections of IL-31 (19 pmol) and low-dose 2AT (30 pmol and 100 pmol) were administered into the shaved left cheek of WT mice. High-dose 2AT (10 nmol) was administrated to both WT and F2rl1–/– (global PAR2 KO) mice. (A) Itch (scratch bouts) and (B) pain (wipe bouts) were scored up to 30 minutes after injections. IL-31 caused both significant scratching and wiping compared with baseline. However, low doses of 2AT (PAR2-specific concentrations) caused only pain behaviors and not scratching. High-dose 2AT (PAR2-nonspecific concentration) caused scratching but not significant wiping in WT mice. In F2rl1–/– mice, high-dose 2AT caused wiping but not significant scratching. n = 4, n = 6, n = 6, and n = 4 for WT mice treated with IL-31 (30 pmol) and 2AT (30 pmol, 100 pmol, and 10 nmol), respectively; n = 6 for F2rl1–/– mice treated with 2AT (10 nmol). Data are expressed as mean ± SEM. Two-way ANOVA with Bonferroni’s multiple comparisons (baseline versus treatment) **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts